Only 27% of Prostate Cancer Docs Use Quality-of-Life Tools

This article originally appeared here.
Share this content:
Quality-of-Life Tools Underused by Prostate Cancer Docs
Quality-of-Life Tools Underused by Prostate Cancer Docs

(HealthDay News) -- More than half of radiation oncologists and urologists in the United States use prostate cancer nomograms, but only about one-quarter use quality-of-life and life-expectancy prediction instruments, according to a study published in the June issue of The Journal of Urology.

Simon P. Kim, M.D., M.P.H., from the Mayo Clinic in Rochester, Minn., and colleagues used a nationally representative mail survey of prostate cancer specialists (313 radiation oncologists and 328 urologists) to assess clinical implementation of quality-of-life instruments, prostate cancer nomograms, and life-expectancy prediction tools in late 2011.

The researchers found that 55%, 27%, and 23% of the respondents reported using prostate cancer nomograms, quality-of-life instruments, and life-expectancy prediction instruments, respectively. Compared with radiation oncologists, urologists were significantly less likely to use quality-of-life instruments (odds ratio, 0.40). Compared with physicians who spent less than 15 minutes counseling patients, those who spent 30 minutes or more were significantly more likely to use quality-of-life instruments, prostate cancer nomograms, and life-expectancy prediction tools (odds ratios, 2.57, 1.83, and 1.85, respectively).

"Although prostate cancer nomograms have been implemented into clinical practice to some degree, the use of quality-of-life and life-expectancy tools has been more limited," the authors write. "Increased attention to implementing validated instruments into clinical practice may facilitate shared decision making for patients with prostate cancer."

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs